Janux Therapeutics Inc
januxrx.comJanux Therapeutics (NASDAQ: JANX) is a clinical-stage biopharmaceutical company developing immunotherapies for cancer and autoimmune diseases using three proprietary platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). The company has no approved products and generates no product revenue, operating entirely on capital raises to fund research and clinical development. Its two clinical-stage candidates are JANX007, a prostate-specific membrane antigen (PSMA) TRACTr in clinical trials for prostate cancer, and JANX008, an EGFR TRACTr in Phase 1 trials across multiple solid tumor types, with Phase 1a expansion cohorts initiated in December 2025. All other programs remain in preclinical or discovery stages as of the FY2025 10-K filed February 26, 2026. The ARM platform targets autoimmune diseases and oncology, with lead programs in nonclinical development. The company relies on third-party contract research organizations for clinical trial conduct and has a limited history of human clinical testing.
Products & Services
JANX007 (PSMA-targeting TRACTr, clinical-stage, prostate cancer); JANX008 (EGFR-targeting TRACTr, Phase 1 expansion cohorts initiated December 2025, multiple solid tumors); ARM platform lead candidates (nonclinical, autoimmune and oncology); TRACIr platform bispecifics with CD28 costimulatory binding domain (research stage).
Revenue Model
Pre-revenue clinical-stage company. Funding comes from equity capital raises. No product sales, royalties, or partnership milestone revenue is described as a current income source in the FY2025 filing.
Customers & Markets
End markets are oncology (solid tumors, prostate cancer) and autoimmune diseases. No commercial customers as of FY2025. Target patient populations are those ineligible for or who have failed prior treatments.
Geographic Exposure
Primary operations in the United States. Filing notes regulatory developments in both the United States and foreign countries as relevant risk factors, but no specific international commercial footprint is described.
Financial Snapshot
Loading...
